StockIQpro
NASDAQ:AMRX

Amneal Pharmaceuticals, Inc.

Track all markets on TradingView
Track all markets on TradingView

Amneal Pharmaceuticals, Inc.'s revenue grew 8.0% in fiscal 2025 to $3.0B while operating margin rose to 13.1%. Free cash flow was $269.9M, 8.9% of revenue, and the diluted share count rose 5.1%.Summary generated from Amneal Pharmaceuticals, Inc.'s SEC filings. Latest annual report filed Feb 27, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$3.0B
Revenue growth+8.0%
Revenue, 5-yr CAGR+8.7%
Gross margin36.9%
Operating margin13.1%
Net margin2.4%
ROIC16.5%
Return on equityn/a
Debt / equityn/a
Free cash flow$269.9M
FCF margin8.9%
Share count change+5.1%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue2,0942,2122,3942,7943,019
Operating income153−95204249394
Net income13−271−84−11772
Free cash flow19419302243270

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations